Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03053063 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 883
- Enrollment target
NCT03053063 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 883 participants.
The verdict
NCT03053063, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 883 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
Interventions
- DRUG SEL
- DRUG Placebo to match SEL 6 mg
- DRUG Placebo to match SEL 18 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 883 participants |
| Start Date | 2017-01-30 |
| Est. Completion | 2019-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03053063
The ClinicalTrials.gov registry entry for NCT03053063 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 883 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SEL is the first listed.
NCT03053063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03053063 about?
NCT03053063 is a clinical study titled "Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)". The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
What is the current status of trial NCT03053063?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 883 participants. The study started on 2017-01-30. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT03053063?
The interventions under investigation include: SEL (DRUG), Placebo to match SEL 6 mg (DRUG), Placebo to match SEL 18 mg (DRUG).
Who is sponsoring clinical trial NCT03053063?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.